2.we found that colorectal cancer patients with HER-2 amplification have a shorter duration of response to EGFR monoclonal antibody therapy and worse prognosis compared to those with wild-type RAS/BRAF, approaching even those with RAS or BRAF mutations 3. This evidence concerns the gene BRAF and colorectal cancer.